Delays in Diagnosis and Treatment of Breast Cancer: A Safety-Net Population Profile

被引:35
|
作者
Jaiswal, Kshama [1 ,2 ]
Hull, Madelyne [3 ]
Furniss, Anna L. [4 ]
Doyle, Reina [5 ]
Gayou, Natalia [5 ]
Bayliss, Elizabeth [6 ,7 ]
机构
[1] Univ Colorado, Dept Surg, Sch Med, Aurora, CO USA
[2] Denver Hlth Med Ctr, Dept Surg, 777 Bannock St,MC 0206, Denver, CO 80204 USA
[3] Denver Hlth Med Ctr, Dept Med, Denver, CO USA
[4] Univ Colorado, Sch Med, ACCORDS, Aurora, CO USA
[5] Denver Hlth Med Ctr, Hlth Serv Res, Denver, CO USA
[6] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA
[7] Univ Colorado, Sch Med, Dept Family Med, Denver, CO USA
关键词
ADJUVANT CHEMOTHERAPY; AFRICAN-AMERICAN; NATIONAL BREAST; WAIT TIMES; RADIOTHERAPY; TIMELINESS; INITIATION; COHORT; WOMEN; CARE;
D O I
10.6004/jnccn.2018.7067
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods: We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from presentation to diagnosis, diagnosis to first treatment, last surgery to chemotherapy initiation, and last surgery to start of radiation therapy (RT). Using logistic regression, we calculated unadjusted odds of receiving timely treatment (< median time) versus more delayed treatment (>= median time) as a function of age, language, ethnicity, insurance, Charlson comorbidity index, disease stage, method of first presentation (screening mammography vs care provider), symptoms at presentation, and type of surgical treatment. Results: Patients aged 55 to 64 years accounted for most of the sample (n=37; 35.2%). Median time from presentation to diagnosis (23 days), time from diagnosis to first treatment, and time from surgery to chemotherapy initiation fell within intervals published in the literature; median time from last surgery to start of RT was greater than recommended intervals. Factors significantly associated with longer intervals than median time included stage, method of presentation, language, surgical treatment, insurance, and ethnicity. Conclusions: Patients in this safety-net setting experienced acceptable diagnosis and treatment intervals, except for time to RT. Focused interventions that help care providers access imaging quickly for their symptomatic patients could improve time to diagnosis. Concentrating additional efforts on non-English-speaking, Hispanic patients and those who need to receive RT could improve time to treatment.
引用
收藏
页码:1451 / 1457
页数:7
相关论文
共 50 条
  • [41] Timeliness of multimodal care for at-risk breast cancer patients at a safety-net institution
    Silva, Trevor
    Lee, Esther
    Tavassoli, Morvarid
    Nguyen, Annie
    Vu, Brandon
    Sinjali, Kiran
    Allison-Aipa, Timothy
    Caba, David
    Lum, Sharon
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 118 - 119
  • [42] ERADICATION RATES OF EMPIRIC HELICOBACTER PYLORI TREATMENT REGIMENS IN A US SAFETY-NET POPULATION
    Kim, Min
    Gonzalez, Isiah
    Choi, Nia
    Kastuar, Shivani
    Patel, Ankur
    El-Serag, Hashem B.
    Tan, Mimi C.
    GASTROENTEROLOGY, 2024, 166 (05) : S437 - S437
  • [43] Barriers to Colorectal Cancer Screening in a Racially Diverse Population Served by a Safety-Net Clinic
    Elizabeth Nagelhout
    Kristen Comarell
    N. Jewel Samadder
    Yelena P. Wu
    Journal of Community Health, 2017, 42 : 791 - 796
  • [44] Prospective breast biopsy collection at an urban safety-net hospital serving a diverse patient population
    Ilinski, Adrian
    Mahdaviani, Kiana
    Fishman, Michael
    Cassidy, Michael
    Ko, Naomi
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Barriers to Colorectal Cancer Screening in a Racially Diverse Population Served by a Safety-Net Clinic
    Nagelhout, Elizabeth
    Comarell, Kristen
    Samadder, N. Jewel
    Wu, Yelena P.
    JOURNAL OF COMMUNITY HEALTH, 2017, 42 (04) : 791 - 796
  • [46] Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals
    Vikrom K. Dhar
    Richard S. Hoehn
    Young Kim
    Brent T. Xia
    Andrew D. Jung
    Dennis J. Hanseman
    Syed A. Ahmad
    Shimul A. Shah
    Journal of Gastrointestinal Surgery, 2018, 22 : 98 - 106
  • [47] Delays in diagnosis and treatment of breast cancer: a multinational analysis
    Jassem, Jacek
    Ozmen, Vahit
    Bacanu, Florin
    Drobniene, Monika
    Eglitis, Janis
    Lakshmaiah, Kuntegowdanahalli C.
    Kahan, Zsuzsanna
    Mardiak, Jozef
    Pienkowski, Tadeusz
    Semiglazova, Tatiana
    Stamatovic, Ljiljana
    Timcheva, Constanta
    Vasovic, Suzana
    Vrbanec, Damir
    Zaborek, Piotr
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2014, 24 (05): : 761 - 767
  • [48] Caution Ahead: Research Challenges of a Randomized Controlled Trial Implemented to Improve Breast Cancer Treatment at Safety-Net Hospitals
    Bickell, Nina A.
    Shah, Ajay
    Castaldi, Maria
    Lewis, Theophilus
    Sickles, Alan
    Arora, Shalini
    Clarke, Kevin
    Kemeny, Margaret
    Srinivasan, Anitha
    Fei, Kezhen
    Franco, Rebeca
    Parides, Michael
    Pappas, Peter
    McAlearney, Ann Scheck
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (03) : E158 - E167
  • [49] Impact of COVID-19 Restrictions on Stage of Breast Cancer at Presentation and Time to Treatment at an Urban Safety-Net Hospital
    Kelly A. Kapp
    An-Lin Cheng
    Catherine M. Bruton
    Nasim Ahmadiyeh
    Annals of Surgical Oncology, 2022, 29 : 6189 - 6196
  • [50] Factors associated with oncotype and recurrence among a diverse breast cancer population seeking care at an urban safety-net hospital.
    Wang, Judy Jiaqi
    Beaulieu-Jones, Brendin
    Acevedo, Jose
    Oshry, Lauren
    Merrill, Andrea
    Hirsch, Ariel
    Cassidy, Michael Ryan
    Ko, Naomi Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)